Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $53.57 +1.15%
Financial Fact:
General and administrative: 997K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
General and administrative: 997K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 revenue of $555 million, versus $511 million reported last year.
- Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
